Free Trial
OTCMKTS:BICX

Biocorrx 3/31/2026 Earnings Report

Biocorrx logo
$0.24 0.00 (0.00%)
As of 05/4/2026 09:30 AM Eastern

Biocorrx EPS Results

Actual EPS
$0.05
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Biocorrx Revenue Results

Actual Revenue
($0.15) million
Expected Revenue
$0.22 million
Beat/Miss
Missed by -$370.00 thousand
YoY Revenue Growth
N/A

Biocorrx Announcement Details

Quarter
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biocorrx's next earnings date is estimated for Monday, May 11, 2026, based on past reporting schedules.

Conference Call Resources

Biocorrx Earnings Headlines

BioCorRx Inc.
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
See More Biocorrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email.

About Biocorrx

Biocorrx (OTCMKTS:BICX), through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

View Biocorrx Profile